Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells
Irinotecan is a natural alkaloid agent widely used in cancer therapy. High-mobility group protein B1 as a non-histone chromosomal protein plays a fundamental role in gene expression and inflammation. In this study, the effect of irinotecan on high-mobility group protein B1 and MMP9 content, gene exp...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-04-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317698354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850053342486593536 |
|---|---|
| author | Saeedeh Keyvani-Ghamsari Azra Rabbani-Chadegani Javad Sargolzaei Maryam Shahhoseini |
| author_facet | Saeedeh Keyvani-Ghamsari Azra Rabbani-Chadegani Javad Sargolzaei Maryam Shahhoseini |
| author_sort | Saeedeh Keyvani-Ghamsari |
| collection | DOAJ |
| description | Irinotecan is a natural alkaloid agent widely used in cancer therapy. High-mobility group protein B1 as a non-histone chromosomal protein plays a fundamental role in gene expression and inflammation. In this study, the effect of irinotecan on high-mobility group protein B1 and MMP9 content, gene expression, cell cycle, and cell growth in human breast cancer cells (MCF-7) was investigated. The cells were exposed to various concentrations of irinotecan and the viability determined by trypan blue exclusion and 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide assays. High-mobility group B proteins were extracted from the control and drug-treated cells and analyzed by immunoblot. High-mobility group protein B1 and MMP9 messenger RNA expression was studied by reverse transcription polymerase chain reaction. The results demonstrated reduction of cell viability upon increasing irinotecan concentration, up-regulated high-mobility group protein B1 gene expression, and down-regulated MMP9 mRNA. Although the content of high-mobility group protein B1 was decreased in chromatin extract upon drug action, no high-mobility group protein B1 release to extracellular space was detected by immunoblot analysis. Irinotecan decreased H3K9 acetylation and increased poly ADP-ribose polymerase fragmentation to 89 kDa and anion superoxide production suggesting induction of apoptosis in these cells. Propidium iodide staining of the cells 24 h after the drug treatment revealed arrest of the cells in S-phase. From the results, it is concluded that overexpression of high-mobility group protein B1 in the presence of irinotecan precedes breast cancer cells into apoptosis and in this response the binding of irinotecan to chromatin or high-mobility group protein B1 may condense/aggregate chromatin, preventing high-mobility group protein B1 release from chromatin. |
| format | Article |
| id | doaj-art-722d2bf018ba409db59a7025f9d3ece3 |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-722d2bf018ba409db59a7025f9d3ece32025-08-20T02:52:34ZengSAGE PublishingTumor Biology1423-03802017-04-013910.1177/1010428317698354Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cellsSaeedeh Keyvani-Ghamsari0Azra Rabbani-Chadegani1Javad Sargolzaei2Maryam Shahhoseini3Department of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IranDepartment of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IranDepartment of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IranDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, Tehran, IranIrinotecan is a natural alkaloid agent widely used in cancer therapy. High-mobility group protein B1 as a non-histone chromosomal protein plays a fundamental role in gene expression and inflammation. In this study, the effect of irinotecan on high-mobility group protein B1 and MMP9 content, gene expression, cell cycle, and cell growth in human breast cancer cells (MCF-7) was investigated. The cells were exposed to various concentrations of irinotecan and the viability determined by trypan blue exclusion and 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide assays. High-mobility group B proteins were extracted from the control and drug-treated cells and analyzed by immunoblot. High-mobility group protein B1 and MMP9 messenger RNA expression was studied by reverse transcription polymerase chain reaction. The results demonstrated reduction of cell viability upon increasing irinotecan concentration, up-regulated high-mobility group protein B1 gene expression, and down-regulated MMP9 mRNA. Although the content of high-mobility group protein B1 was decreased in chromatin extract upon drug action, no high-mobility group protein B1 release to extracellular space was detected by immunoblot analysis. Irinotecan decreased H3K9 acetylation and increased poly ADP-ribose polymerase fragmentation to 89 kDa and anion superoxide production suggesting induction of apoptosis in these cells. Propidium iodide staining of the cells 24 h after the drug treatment revealed arrest of the cells in S-phase. From the results, it is concluded that overexpression of high-mobility group protein B1 in the presence of irinotecan precedes breast cancer cells into apoptosis and in this response the binding of irinotecan to chromatin or high-mobility group protein B1 may condense/aggregate chromatin, preventing high-mobility group protein B1 release from chromatin.https://doi.org/10.1177/1010428317698354 |
| spellingShingle | Saeedeh Keyvani-Ghamsari Azra Rabbani-Chadegani Javad Sargolzaei Maryam Shahhoseini Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells Tumor Biology |
| title | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells |
| title_full | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells |
| title_fullStr | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells |
| title_full_unstemmed | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells |
| title_short | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells |
| title_sort | effect of irinotecan on hmgb1 mmp9 expression cell cycle and cell growth in breast cancer mcf 7 cells |
| url | https://doi.org/10.1177/1010428317698354 |
| work_keys_str_mv | AT saeedehkeyvanighamsari effectofirinotecanonhmgb1mmp9expressioncellcycleandcellgrowthinbreastcancermcf7cells AT azrarabbanichadegani effectofirinotecanonhmgb1mmp9expressioncellcycleandcellgrowthinbreastcancermcf7cells AT javadsargolzaei effectofirinotecanonhmgb1mmp9expressioncellcycleandcellgrowthinbreastcancermcf7cells AT maryamshahhoseini effectofirinotecanonhmgb1mmp9expressioncellcycleandcellgrowthinbreastcancermcf7cells |